A
Astra M. Liepa
Researcher at Eli Lilly and Company
Publications - 92
Citations - 4138
Astra M. Liepa is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Cancer & Ramucirumab. The author has an hindex of 23, co-authored 87 publications receiving 3556 citations.
Papers
More filters
Journal ArticleDOI
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,G. Aprile,David Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Zalcberg,John Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M. Liepa,Ling Gao,Jonathan D. Schwartz,Josep Tabernero +24 more
TL;DR: Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, and validate VEGFR-2 signalling as an important therapeutic target in advanced Gastric cancer.
Journal ArticleDOI
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick,Vinay K. Puduvalli,Marc C. Chamberlain,Martin J. van den Bent,Antoine F. Carpentier,Lawrence Cher,Warren P. Mason,Michael Weller,Shengyan Hong,Luna Musib,Astra M. Liepa,Donald Thornton,Howard A. Fine +12 more
TL;DR: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.
Journal ArticleDOI
What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures?
TL;DR: This article focuses on the necessary psychometric properties of a patient-reported outcomes (PROs) measure and the kinds of evidence needed to indicate that a PRO has a sufficient level of reliability and validity.
Journal ArticleDOI
Health-Related Quality-of-Life Parameters as Independent Prognostic Factors in Advanced or Metastatic Bladder Cancer
TL;DR: HRQoL parameters are independent prognostic factors for outcome in advanced bladder cancer; their prognostic importance needs further evaluation.
Journal ArticleDOI
Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
Robert W. Klein,Ronald C. Wielage,Catherine Muehlenbein,Astra M. Liepa,S.M. Babineaux,Anthony H. Lawson,Lee S. Schwartzberg +6 more
TL;DR: This analysis is the first to evaluate the cost-effectiveness of maintenance therapy with pemetrexed in advanced NSCLC and emphasizes the importance of histology in identifying the appropriate patient for Pem maintenance therapy.